NEUROCRINE BIOSCIENCES INC (NBIX) Stock Fundamental Analysis
USA - NASDAQ:NBIX - US64125C1099 - Common Stock
152.37 USD
-2.43 (-1.57%)
152.37 USD
0 (0%)
Taking everything into account, NBIX scores 7 out of 10 in our fundamental rating. NBIX was compared to 534 industry peers in the Biotechnology industry. Both the health and profitability get an excellent rating, making NBIX a very profitable company, without any liquidiy or solvency issues. NBIX is evaluated to be cheap and growing strongly. This does not happen too often! With these ratings, NBIX could be worth investigating further for value and growth and quality investing!.
1. Profitability
1.1 Basic Checks
NBIX had positive earnings in the past year.
NBIX had a positive operating cash flow in the past year.
In the past 5 years NBIX has always been profitable.
NBIX had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
The Return On Assets of NBIX (10.03%) is better than 94.01% of its industry peers.
Looking at the Return On Equity, with a value of 14.25%, NBIX belongs to the top of the industry, outperforming 94.38% of the companies in the same industry.
The Return On Invested Capital of NBIX (11.10%) is better than 94.57% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for NBIX is below the industry average of 15.40%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 10.03% | ||
| ROE | 14.25% | ||
| ROIC | 11.1% |
ROA(3y)7.79%
ROA(5y)10.24%
ROE(3y)11.14%
ROE(5y)15.22%
ROIC(3y)11.4%
ROIC(5y)11.57%
1.3 Margins
NBIX has a better Profit Margin (15.95%) than 93.63% of its industry peers.
In the last couple of years the Profit Margin of NBIX has grown nicely.
The Operating Margin of NBIX (20.64%) is better than 94.76% of its industry peers.
In the last couple of years the Operating Margin of NBIX has declined.
NBIX's Gross Margin of 98.37% is amongst the best of the industry. NBIX outperforms 97.38% of its industry peers.
NBIX's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 20.64% | ||
| PM (TTM) | 15.95% | ||
| GM | 98.37% |
OM growth 3Y10.53%
OM growth 5Y-2.95%
PM growth 3Y22.39%
PM growth 5Y25.28%
GM growth 3Y-0.06%
GM growth 5Y-0.1%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), NBIX is creating some value.
The number of shares outstanding for NBIX has been increased compared to 1 year ago.
NBIX has more shares outstanding than it did 5 years ago.
NBIX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
An Altman-Z score of 8.88 indicates that NBIX is not in any danger for bankruptcy at the moment.
NBIX has a better Altman-Z score (8.88) than 82.40% of its industry peers.
NBIX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 8.88 |
ROIC/WACC1.27
WACC8.71%
2.3 Liquidity
A Current Ratio of 3.38 indicates that NBIX has no problem at all paying its short term obligations.
NBIX has a Current ratio of 3.38. This is in the lower half of the industry: NBIX underperforms 61.24% of its industry peers.
A Quick Ratio of 3.27 indicates that NBIX has no problem at all paying its short term obligations.
NBIX's Quick ratio of 3.27 is in line compared to the rest of the industry. NBIX outperforms 40.82% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.38 | ||
| Quick Ratio | 3.27 |
3. Growth
3.1 Past
NBIX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 12.06%, which is quite good.
NBIX shows a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 58.39% yearly.
NBIX shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 19.61%.
Measured over the past years, NBIX shows a very strong growth in Revenue. The Revenue has been growing by 24.48% on average per year.
EPS 1Y (TTM)12.06%
EPS 3Y35.58%
EPS 5Y58.39%
EPS Q2Q%64.52%
Revenue 1Y (TTM)19.61%
Revenue growth 3Y27.61%
Revenue growth 5Y24.48%
Sales Q2Q%27.78%
3.2 Future
The Earnings Per Share is expected to grow by 35.05% on average over the next years. This is a very strong growth
The Revenue is expected to grow by 12.49% on average over the next years. This is quite good.
EPS Next Y53.46%
EPS Next 2Y44.8%
EPS Next 3Y36.99%
EPS Next 5Y35.05%
Revenue Next Year21.48%
Revenue Next 2Y19.74%
Revenue Next 3Y15.88%
Revenue Next 5Y12.49%
3.3 Evolution
Although the future EPS growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings ratio is 36.45, which means the current valuation is very expensive for NBIX.
NBIX's Price/Earnings ratio is rather cheap when compared to the industry. NBIX is cheaper than 92.51% of the companies in the same industry.
The average S&P500 Price/Earnings ratio is at 25.83. NBIX is valued slightly more expensive when compared to this.
The Price/Forward Earnings ratio is 22.09, which indicates a rather expensive current valuation of NBIX.
92.13% of the companies in the same industry are more expensive than NBIX, based on the Price/Forward Earnings ratio.
NBIX is valuated rather cheaply when we compare the Price/Forward Earnings ratio to 32.68, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 36.45 | ||
| Fwd PE | 22.09 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, NBIX is valued cheaply inside the industry as 93.07% of the companies are valued more expensively.
94.38% of the companies in the same industry are more expensive than NBIX, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 25.48 | ||
| EV/EBITDA | 23.08 |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
NBIX has an outstanding profitability rating, which may justify a higher PE ratio.
NBIX's earnings are expected to grow with 36.99% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.68
PEG (5Y)0.62
EPS Next 2Y44.8%
EPS Next 3Y36.99%
5. Dividend
5.1 Amount
NBIX does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
152.37
-2.43 (-1.57%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners100.77%
Inst Owner Change-0.37%
Ins Owners1.01%
Ins Owner Change0.59%
Market Cap15.11B
Revenue(TTM)2.68B
Net Income(TTM)428.00M
Analysts84.57
Price Target172.44 (13.17%)
Short Float %4.48%
Short Ratio5.59
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)16.55%
Min EPS beat(2)7%
Max EPS beat(2)26.1%
EPS beat(4)2
Avg EPS beat(4)-22.42%
Min EPS beat(4)-85.62%
Max EPS beat(4)26.1%
EPS beat(8)3
Avg EPS beat(8)-23.05%
EPS beat(12)4
Avg EPS beat(12)-75.32%
EPS beat(16)4
Avg EPS beat(16)-76.53%
Revenue beat(2)2
Avg Revenue beat(2)3.84%
Min Revenue beat(2)3.28%
Max Revenue beat(2)4.39%
Revenue beat(4)2
Avg Revenue beat(4)1.34%
Min Revenue beat(4)-2.16%
Max Revenue beat(4)4.39%
Revenue beat(8)4
Avg Revenue beat(8)1.12%
Revenue beat(12)6
Avg Revenue beat(12)0.97%
Revenue beat(16)9
Avg Revenue beat(16)1.1%
PT rev (1m)1.97%
PT rev (3m)5.47%
EPS NQ rev (1m)0.53%
EPS NQ rev (3m)26.83%
EPS NY rev (1m)1.45%
EPS NY rev (3m)15.36%
Revenue NQ rev (1m)0.2%
Revenue NQ rev (3m)5.57%
Revenue NY rev (1m)0.18%
Revenue NY rev (3m)4.09%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 36.45 | ||
| Fwd PE | 22.09 | ||
| P/S | 5.63 | ||
| P/FCF | 25.48 | ||
| P/OCF | 23.73 | ||
| P/B | 5.03 | ||
| P/tB | 5.09 | ||
| EV/EBITDA | 23.08 |
EPS(TTM)4.18
EY2.74%
EPS(NY)6.9
Fwd EY4.53%
FCF(TTM)5.98
FCFY3.92%
OCF(TTM)6.42
OCFY4.21%
SpS27.05
BVpS30.28
TBVpS29.92
PEG (NY)0.68
PEG (5Y)0.62
Graham Number53.37
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 10.03% | ||
| ROE | 14.25% | ||
| ROCE | 15.26% | ||
| ROIC | 11.1% | ||
| ROICexc | 16.02% | ||
| ROICexgc | 16.25% | ||
| OM | 20.64% | ||
| PM (TTM) | 15.95% | ||
| GM | 98.37% | ||
| FCFM | 22.11% |
ROA(3y)7.79%
ROA(5y)10.24%
ROE(3y)11.14%
ROE(5y)15.22%
ROIC(3y)11.4%
ROIC(5y)11.57%
ROICexc(3y)30.35%
ROICexc(5y)27.29%
ROICexgc(3y)31.58%
ROICexgc(5y)28.03%
ROCE(3y)15.68%
ROCE(5y)15.92%
ROICexgc growth 3Y35.59%
ROICexgc growth 5Y-0.37%
ROICexc growth 3Y34.3%
ROICexc growth 5Y-0.94%
OM growth 3Y10.53%
OM growth 5Y-2.95%
PM growth 3Y22.39%
PM growth 5Y25.28%
GM growth 3Y-0.06%
GM growth 5Y-0.1%
F-Score5
Asset Turnover0.63
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 147.14% | ||
| Cap/Sales | 1.63% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 109.17% | ||
| Profit Quality | 138.57% | ||
| Current Ratio | 3.38 | ||
| Quick Ratio | 3.27 | ||
| Altman-Z | 8.88 |
F-Score5
WACC8.71%
ROIC/WACC1.27
Cap/Depr(3y)126.53%
Cap/Depr(5y)144.2%
Cap/Sales(3y)1.41%
Cap/Sales(5y)1.47%
Profit Quality(3y)172.36%
Profit Quality(5y)166.13%
High Growth Momentum
Growth
EPS 1Y (TTM)12.06%
EPS 3Y35.58%
EPS 5Y58.39%
EPS Q2Q%64.52%
EPS Next Y53.46%
EPS Next 2Y44.8%
EPS Next 3Y36.99%
EPS Next 5Y35.05%
Revenue 1Y (TTM)19.61%
Revenue growth 3Y27.61%
Revenue growth 5Y24.48%
Sales Q2Q%27.78%
Revenue Next Year21.48%
Revenue Next 2Y19.74%
Revenue Next 3Y15.88%
Revenue Next 5Y12.49%
EBIT growth 1Y-5.9%
EBIT growth 3Y41.04%
EBIT growth 5Y20.8%
EBIT Next Year2.32%
EBIT Next 3Y23.13%
EBIT Next 5Y19.04%
FCF growth 1Y54.17%
FCF growth 3Y33.71%
FCF growth 5Y32.31%
OCF growth 1Y55.54%
OCF growth 3Y32.41%
OCF growth 5Y31.38%
NEUROCRINE BIOSCIENCES INC / NBIX FAQ
What is the fundamental rating for NBIX stock?
ChartMill assigns a fundamental rating of 7 / 10 to NBIX.
What is the valuation status of NEUROCRINE BIOSCIENCES INC (NBIX) stock?
ChartMill assigns a valuation rating of 7 / 10 to NEUROCRINE BIOSCIENCES INC (NBIX). This can be considered as Undervalued.
What is the profitability of NBIX stock?
NEUROCRINE BIOSCIENCES INC (NBIX) has a profitability rating of 8 / 10.
What are the PE and PB ratios of NEUROCRINE BIOSCIENCES INC (NBIX) stock?
The Price/Earnings (PE) ratio for NEUROCRINE BIOSCIENCES INC (NBIX) is 36.45 and the Price/Book (PB) ratio is 5.03.